Malignant Urethral Neoplasm
Associated Genetic Biomarkers
NCI Definition: Abnormal malignant growth of cells in the urethra (lower urinary tract). 
Malignant urethral neoplasms most frequently harbor alterations in TP53, FGFR3, PIK3CA, CDKN2A, and KDM6A .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, FGFR3 Mutation, and TP53 Exon 8 Mutation are the most common alterations in malignant urethral neoplasm .
There are 6 clinical trials for malignant urethral neoplasm, of which 4 are open and 2 are completed or closed. Of the trials that contain malignant urethral neoplasm as an inclusion criterion, 3 are phase 1 (3 open) and 3 are phase 2 (1 open).
ERBB2 and HER2 are the most frequent gene inclusion criteria for malignant urethral neoplasm clinical trials .
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in malignant urethral neoplasm clinical trials.
Significant Genes in Malignant Urethral Neoplasm
ERBB2 is altered in 7.78% of malignant urethral neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant urethral neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant urethral neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.